Amount of cash payable upon the achievement of certain milestones based on the research agreement.

No definition available.

Name:	mcet_CashPayableUponClinicalDevelopmentMilestones
Namespace Prefix:	mcet_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

It represents option to purchase manufacturing rights upon payment amount as on the reporting period.

+ References

No definition available.

+ Details

Name:	mcet_OptionToPurchaseManufacturingRightsUponPayableAmount
Namespace Prefix:	mcet_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The percentage represents net sublicense revenue during the reporting period.

+ References

No definition available.

+ Details

Name:	mcet_PercentageOfNetSublicenseRevenue
Namespace Prefix:	mcet_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

It represents percentage of royalty payable.

+ References

No definition available.

+ Details

Name:	mcet_PercentageOfRoyaltyPayable
Namespace Prefix:	mcet_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

It represents the reimbursable total under research agreement during the reporting period.

+ References

No definition available.

+ Details

Name:	mcet_ReimbursableTotalUnderResearchAgreement
Namespace Prefix:	mcet_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The maximum number of common shares permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name:	us-gaap_CommonStockSharesAuthorized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

Costs incurred and are directly related to generating license revenue. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.2(e))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name:	us-gaap_LicenseCosts
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_SubsequentEventLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

SUBSEQUENT EVENTS (Details Textual) (USD $)	0 Months Ended
SUBSEQUENT EVENTS (Details Textual) (USD $)	Mar. 10, 2015	Feb. 28, 2015	Nov. 30, 2014	Mar. 11, 2015
Subsequent Event [Line Items]
Common Stock, Shares Authorized		5,000,000,000us-gaap_CommonStockSharesAuthorized	5,000,000,000us-gaap_CommonStockSharesAuthorized
Subsequent Event [Member] \| Oxis Biotech, Inc [Member]
Subsequent Event [Line Items]
Percentage Of Net Sublicense Revenue	30.00%
Percentage Of Royalty Payable	3.00%
Option To Purchase Manufacturing Rights Upon Payable Amount	$ 10,000,000
Cash Payable Upon Clinical Development Milestones	12,750,000
License Costs	500,000
Reimbursable Total Under Research Agreement	1,125,000
Subsequent Event [Member] \| MultiCell Immunotherapeutics, Inc. [Member]
Subsequent Event [Line Items]
License Costs	$ 375,000
Subsequent Event [Member] \| Prior To Amendment [Member]
Subsequent Event [Line Items]
Common Stock, Shares Authorized				5,000,000,000
Subsequent Event [Member] \| After To Amendment [Member]
Subsequent Event [Line Items]
Common Stock, Shares Authorized				10,000,000,000